Shares of Biogen (BIIB) soared Friday after the biotech company's early clinical trial data of its experimental Alzheimer's drug was leaked Thursday afternoon. This comes as competitor Eli Lilly (LLY) reported that its late stage study for Alzheimer's failed. Eli Lilly says it "nearly hit" its primary endpoint of cognition improvement at 18 months. Following Biogen's phase 3 drug's positive data, Robert Baird analysts increased their outlook for a probability of success from 25% to 40% and increased their target price to $309 from $284. Baird analysts rate Biogen's stock as neutral. TheStreet's Sarah Pringle says the latest developments around the Biogen and Lilly studies comes as other drugmakers double down on their efforts to find a cure for Alzheimer's disease.
More from Video
How quickly do we find support, is what we'll want to know now, as the correction is occurring while economic optimism builds.
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.